Wide Ranks

EXEL

Exelixis, Inc.

35.93

Top Statistics
Market Cap 10 B Forward PE 18.31 Revenue Growth 14.30 %
Current Ratio 3.93 Trailing PE 23.18 Earnings Growth 12169.90 %
Profit Margins 22.43 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 14.57 Enterprise / Revenue 4.45 Price To Sales Trailing12 Months 4.93
Profitability
Profit Margins 22.43 % Operating Margins 34.81 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 4.16 Total Debt 194 M
Total Debt To Equity 8.54 Current Ratio 3.93 Book Value Per Share 7.96
All Measures
Short Ratio 276.00 % Message Board Id finmb_28338 Fax 650 837 8300
Shares Short Prior Month 9 M Return On Equity 0.2020 City Alameda
Uuid 3d2b06c7-e4e4-3c4b-a972-6c6bfa8d57a3 Previous Close 36.45 First Trade Date Epoch Utc 955 M
Book Value 7.96 Beta 0.5110 Total Debt 194 M
Volume 1 M Price To Book 4.51 Fifty Two Week Low 19.20
Total Cash Per Share 4.16 Total Revenue 2 B Shares Short Previous Month Date 1 B
Target Median Price 33.50 Max Age 86400 Recommendation Mean 2.05
Sand P52 Week Change 0.3133 Operating Margins 34.81 % Target Mean Price 31.83
Net Income To Common 466 M Short Percent Of Float 0.0372 Implied Shares Outstanding 285 M
Trailing Peg Ratio 260.98 % Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 1 B Next Fiscal Year End 1 B
Revenue Per Share 7.03 Held Percent Insiders 0.0160 Ebitda Margins 30.55 %
Trailing PE 23.18 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 36.45 Target Low Price 18.90 Gmt Off Set Milliseconds -18000000
Fifty Day Average 30.44 Open 36.45 Free Cashflow 431 M
State CA Dividend Yield 0.00 % Return On Assets 0.1281
Time Zone Short Name EST Trailing Eps 1.55 Day Low 35.57
Address1 1851 Harbor Bay Parkway Shares Outstanding 285 M Price Hint 2
Target High Price 38.00 Website https://www.exelixis.com 52 Week Change 0.6474
Average Volume 2 M Earnings Quarterly Growth 11232.70 % Forward Eps 1.70
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 373.20 %
Is_sp_500 False Regular Market Day High 36.73 Profit Margins 22.43 %
Debt To Equity 8.54 Fifty Two Week High 36.73 Day High 36.73
Shares Short 7 M Regular Market Open 36.45 Industry Key biotechnology
Earnings Growth 12169.90 % Enterprise To Revenue 4.45 Revenue Growth 14.30 %
Shares Percent Shares Out 0.0277 Operating Cashflow 470 M Currency USD
Time Zone Full Name America/New_York Market Cap 10 B Is_nasdaq_100 False
Zip 94502 Quote Type EQUITY Industry Biotechnology
Long Name Exelixis, Inc. Regular Market Day Low 35.57 Held Percent Institutions 0.8922
Current Price 35.93 Enterprise To Ebitda 14.57 Financial Currency USD
Current Ratio 3.93 Gross Margins 96.25 % Industry Disp Biotechnology
Number Of Analyst Opinions 22 Country United States Float Shares 238 M
Two Hundred Day Average 24.97 Ir Website http://www.exelixis.com/investors-media Enterprise Value 9 B
Price To Sales Trailing12 Months 4.93 Forward PE 18.31 Regular Market Volume 1 M
Ebitda 635 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.

It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload.

It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.

; F.

Hoffmann-La Roche Ltd.

; Redwood Bioscience, Inc.; R.

P.

Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.

V.

and Merck & Co.

, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000.

Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.